Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Abstract
All convalescent plasma..
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchConvalescent PlasmaConv. Plasma (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   All Outcomes    Recent:   

Quality of life and cost‐effectiveness of convalescent plasma compared to standard care for hospitalized COVID‐19 patients in the CONCOR‐1 trial

Tse et al., Transfusion, doi:10.1111/trf.17777, NCT04348656
Mar 2024  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Analysis of the CONCUR-1 RCT showing that convalescent plasma was associated with higher costs, longer hospital stays, and lower quality-adjusted life days.
Tse et al., 21 Mar 2024, Randomized Controlled Trial, Canada, peer-reviewed, 21 authors, study period 14 May, 2020 - 29 January, 2021, trial NCT04348656 (history). Contact: fengxie@mcmaster.ca.
This PaperConv. PlasmaAll
Quality of life and cost‐effectiveness of convalescent plasma compared to standard care for hospitalized COVID‐19 patients in the CONCOR‐1 trial
Preston Tse, Jiajun Yan, Yang Liu, Erin Jamula, Nancy Heddle, Renée Bazin, Nancy Robitaille, Richard Cook, Alexis Turgeon, Dean Fergusson, Marshall Glesby, Kent Cadogan Loftsgard, Melissa Cushing, Michaël Chassé, Nick Daneman, Andrés Finzi, Bruce Sachais, Philippe Bégin, Jeannie Callum, Donald M Arnold, Feng Xie
Transfusion, doi:10.1111/trf.17777
Background: The CONvalescent Plasma for Hospitalized Adults With COVID-19 Respiratory Illness (CONCOR-1) trial was a multicenter randomized controlled trial assessing convalescent plasma in hospitalized COVID-19 patients. This study evaluates the cost-effectiveness of convalescent plasma and its impact on quality-of-life to provide insight into its potential as an alternative treatment in resource-constrained settings. Methods: Individual patient data on health outcomes and resource utilization from the CONCOR-1 trial were used to conduct the analysis from the Canadian public payer's perspective with a time horizon of 30 days post-randomization. Baseline and 30-day EQ-5D-5L were measured to calculate quality-adjusted survival. All costs are presented in 2021 Canadian dollars. The base case assessed the EQ-5D-5L scores of hospitalized inpatients reporting at both timepoints, and a utility score of 0 was assigned for patients who died within 30 days. Costs for all patients enrolled were used. The sensitivity analysis utilizes EQ-5D-5L scores from the same population but only uses costs from this population. Results: 940 patients were randomized: 627 received CCP and 313 received standard care. The total costs were $28,716 (standard deviation, $25,380) and $24,258 ($22,939) for the convalescent plasma and standard care arms respectively. EQ-5D-5L scores were 0.61 in both arms (p = .85) at baseline. At 30 days, Abbreviations: AEs, adverse events; CCP, convalescent plasma; CONCOR-1, convalescent plasma for hospitalized adults with COVID-19 respiratory illness; ECMO,
SUPPORTING INFORMATION Additional supporting information can be found online in the Supporting Information section at the end of this article.
References
Axfors, Janiaud, Schmitt, Van't Hooft, Smith et al., Association between convalescent plasma treatment and mortality in COVID-19: collaborative systematic review and meta-analysis of randomized clinical trials, BMC Infect Dis
Bégin, Callum, Heddle, Cook, Zeller et al., Convalescent plasma for adults with acute COVID-19 respiratory illness (CONCOR-1): study protocol for an international, multicentre, randomized, open-label trial, Trials
Bégin, Callum, Jamula, Cook, Heddle et al., Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial, Nat Med
De Oliveira, De Ávila, De Oliveira, Da, Severino Sampaio et al., Persistent symptoms, quality of life, and risk factors in long COVID: a crosssectional study of hospitalized patients in Brazil, Int J Infect Dis
Don, Michael, Federico, De B-G, Andrew et al., Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations, BMJ
Estcourt, Turgeon, Mcquilten, Mcverry, Al-Beidh et al., Effect of convalescent plasma on organ support-free days in critically ill patients with COVID-19: a randomized clinical trial, JAMA
Feng, Kohlmann, Janssen, Buchholz, Psychometric properties of the EQ-5D-5L: a systematic review of the literature, Qual Life Res
Fenwick, Claxton, Sculpher, Representing uncertainty: the role of cost-effectiveness acceptability curves, Health Econ
Hamilton, Lee, Arnold, Lilford, Hemming, Is convalescent plasma futile in COVID-19? A Bayesian re-analysis of the RECOVERY randomized controlled trial, Int J Infect Dis
Herdman, Gudex, Lloyd, Janssen, Kind et al., Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L), Qual Life Res
Information, COVID-19 hospitalization and emergency department statistics
Joyner, Carter, Senefeld, Klassen, Mills et al., Convalescent plasma antibody levels and the risk of death from Covid-19, N Engl J Med
Korley, Durkalski-Mauldin, Yeatts, Schulman, Davenport et al., Early convalescent plasma for high-risk outpatients with Covid-19, N Engl J Med
Lang-Meli, Fuchs, Mathé, Ho, Kern et al., Case series: convalescent plasma therapy for patients with COVID-19 and primary antibody deficiency, J Clin Immunol
Libster, Marc, Wappner, Coviello, Bianchi et al., Early high-titer plasma therapy to prevent severe Covid-19 in older adults, N Engl J Med
Ortigoza, Yoon, Goldfeld, Troxel, Daily et al., Efficacy and safety of COVID-19 convalescent plasma in hospitalized patients: a randomized clinical trial, JAMA Intern Med
Piechotta, Chai, Valk, Doree, Monsef et al., Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review, Cochrane Database Syst Rev
Senefeld, Klassen, Ford, Senese, Wiggins et al., Use of convalescent plasma in COVID-19 patients with immunosuppression, Transfusion
Tsuzuki, Miyazato, Terada, Morioka, Ohmagari et al., Impact of long-COVID on health-related quality of life in Japanese COVID-19 patients, Health Qual Life Outcomes
Xie, Pullenayegum, Gaebel, Bansback, Bryan et al., A time trade-off-derived value set of the EQ-5D-5L for Canada, Med Care
{ 'DOI': '10.1111/trf.17777', 'ISSN': ['0041-1132', '1537-2995'], 'URL': 'http://dx.doi.org/10.1111/trf.17777', 'abstract': '<jats:title>Abstract</jats:title><jats:sec><jats:title>Background</jats:title><jats:p>The ' 'CONvalescent Plasma for Hospitalized Adults With COVID‐19 Respiratory Illness (CONCOR‐1) ' 'trial was a multicenter randomized controlled trial assessing convalescent plasma in ' 'hospitalized COVID‐19 patients. This study evaluates the cost‐effectiveness of convalescent ' 'plasma and its impact on quality‐of‐life to provide insight into its potential as an ' 'alternative treatment in resource‐constrained ' 'settings.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>Individual ' 'patient data on health outcomes and resource utilization from the CONCOR‐1 trial were used to ' "conduct the analysis from the Canadian public payer's perspective with a time horizon of " '30\u2009days post‐randomization. Baseline and 30‐day EQ‐5D‐5L were measured to calculate ' 'quality‐adjusted survival. All costs are presented in 2021 Canadian dollars. The base case ' 'assessed the EQ‐5D‐5L scores of hospitalized inpatients reporting at both timepoints, and a ' 'utility score of 0 was assigned for patients who died within 30\u2009days. Costs for all ' 'patients enrolled were used. The sensitivity analysis utilizes EQ‐5D‐5L scores from the same ' 'population but only uses costs from this ' 'population.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>940 patients ' 'were randomized: 627 received CCP and 313 received standard care. The total costs were ' '$28,716 (standard deviation, $25,380) and $24,258 ($22,939) for the convalescent plasma and ' 'standard care arms respectively. EQ‐5D‐5L scores were 0.61 in both arms ' '(<jats:italic>p</jats:italic>\u2009=\u2009.85) at baseline. At 30\u2009days, EQ‐5D‐5L scores ' 'were 0.63 and 0.64 for patients in the convalescent plasma and standard care arms,\xa0' 'respectively (<jats:italic>p</jats:italic>\u2009=\u2009.46). The incremental cost was $4458 ' 'and the incremental quality‐adjusted life day was ' '−0.078.</jats:p></jats:sec><jats:sec><jats:title>Discussion</jats:title><jats:p>Convalescent ' 'plasma was less effective and more costly than standard care in treating hospitalized ' 'COVID‐19.</jats:p></jats:sec>', 'alternative-id': ['10.1111/trf.17777'], 'assertion': [ { 'group': {'label': 'Publication History', 'name': 'publication_history'}, 'label': 'Received', 'name': 'received', 'order': 0, 'value': '2023-09-06'}, { 'group': {'label': 'Publication History', 'name': 'publication_history'}, 'label': 'Accepted', 'name': 'accepted', 'order': 1, 'value': '2024-02-26'}, { 'group': {'label': 'Publication History', 'name': 'publication_history'}, 'label': 'Published', 'name': 'published', 'order': 2, 'value': '2024-03-21'}], 'author': [ { 'affiliation': [ { 'name': 'Department of Health Research Methods, Evidence, and Impact ' 'McMaster University Hamilton Ontario Canada'}], 'family': 'Tse', 'given': 'Preston', 'sequence': 'first'}, { 'affiliation': [ { 'name': 'Department of Health Research Methods, Evidence, and Impact ' 'McMaster University Hamilton Ontario Canada'}], 'family': 'Yan', 'given': 'Jiajun', 'sequence': 'additional'}, { 'affiliation': [ { 'name': 'Michael G. DeGroote Centre for Transfusion Research McMaster ' 'University Hamilton Ontario Canada'}], 'family': 'Liu', 'given': 'Yang', 'sequence': 'additional'}, { 'affiliation': [ { 'name': 'Michael G. DeGroote Centre for Transfusion Research McMaster ' 'University Hamilton Ontario Canada'}], 'family': 'Jamula', 'given': 'Erin', 'sequence': 'additional'}, { 'ORCID': 'http://orcid.org/0000-0002-9671-3501', 'affiliation': [ { 'name': 'Michael G. DeGroote Centre for Transfusion Research McMaster ' 'University Hamilton Ontario Canada'}, { 'name': 'Department of Medicine McMaster University Hamilton Ontario ' 'Canada'}, {'name': 'Canadian Blood Services Ottawa Ontario Canada'}], 'authenticated-orcid': False, 'family': 'Heddle', 'given': 'Nancy', 'sequence': 'additional'}, { 'ORCID': 'http://orcid.org/0000-0001-9594-2532', 'affiliation': [ { 'name': 'Medical Affairs and Innovation, Héma‐Québec Québec City Québec ' 'Canada'}], 'authenticated-orcid': False, 'family': 'Bazin', 'given': 'Renée', 'sequence': 'additional'}, { 'affiliation': [ {'name': 'Héma‐Québec Montreal Québec Canada'}, { 'name': 'Division of Hematology‐Oncology, Department of Pediatrics CHU ' 'Sainte‐Justine Montreal Québec Canada'}], 'family': 'Robitaille', 'given': 'Nancy', 'sequence': 'additional'}, { 'affiliation': [ { 'name': 'Department of Statistics and Actuarial Science University of ' 'Waterloo Waterloo Ontario Canada'}], 'family': 'Cook', 'given': 'Richard', 'sequence': 'additional'}, { 'affiliation': [ { 'name': 'Population Health and Optimal Health Practices Research Unit ' '(Trauma‐Emergency‐Critical Care Medicine) CHU de Québec – ' 'Université Laval Research Center Québec City Québec Canada'}, { 'name': 'Division of Critical Care Medicine, Department of Anesthesiology ' 'and Critical Care Medicine Université Laval Québec City Québec ' 'Canada'}], 'family': 'Turgeon', 'given': 'Alexis', 'sequence': 'additional'}, { 'affiliation': [ {'name': 'Canadian Blood Services Ottawa Ontario Canada'}, { 'name': 'Clinical Epidemiology Program Ottawa Hospital Research ' 'Institute Ottawa Ontario Canada'}, { 'name': 'Department of Medicine University of Ottawa Ottawa Ontario ' 'Canada'}], 'family': 'Fergusson', 'given': 'Dean', 'sequence': 'additional'}, { 'affiliation': [ { 'name': 'Division of Infectious Diseases, Department of Medicine Weill ' 'Cornell Medicine New York New York USA'}], 'family': 'Glesby', 'given': 'Marshall', 'sequence': 'additional'}, { 'affiliation': [ {'name': 'UBC Health Team‐Based Care Vancouver British Columbia USA'}, { 'name': 'CIHR‐Strategy for Patient‐Oriented Research Ottawa Ontario ' 'Canada'}], 'family': 'Loftsgard', 'given': 'Kent Cadogan', 'sequence': 'additional'}, { 'ORCID': 'http://orcid.org/0000-0001-8042-1494', 'affiliation': [ { 'name': 'Department of Pathology and Laboratory Medicine Weill Cornell ' 'Medicine New York New York USA'}], 'authenticated-orcid': False, 'family': 'Cushing', 'given': 'Melissa', 'sequence': 'additional'}, { 'affiliation': [ { 'name': "Department of Medicine Centre Hospitalier de l'Université de " 'Montréal Montreal Québec Canada'}, { 'name': 'Innovation Hub Centre de Recherche du Centre Hospitalier de ' "l'Université de Montréal Montreal Québec Canada"}], 'family': 'Chassé', 'given': 'Michaël', 'sequence': 'additional'}, { 'affiliation': [ { 'name': 'Division of Infectious Diseases, Sunnybrook Health Sciences ' 'Centre, Department of Medicine University of Toronto Toronto ' 'Ontario Canada'}], 'family': 'Daneman', 'given': 'Nick', 'sequence': 'additional'}, { 'ORCID': 'http://orcid.org/0000-0002-4992-5288', 'affiliation': [ {'name': 'Centre de Recherche du CHUM Montreal Québec Canada'}, { 'name': 'Département de Microbiologie, Infectiologie et Immunologie ' 'Université de Montréal Montreal Québec Canada'}], 'authenticated-orcid': False, 'family': 'Finzi', 'given': 'Andrés', 'sequence': 'additional'}, { 'affiliation': [ {'name': 'New York Blood Center New York New York USA'}, {'name': 'Weil Cornell Medical College New York New York USA'}], 'family': 'Sachais', 'given': 'Bruce', 'sequence': 'additional'}, { 'affiliation': [ { 'name': "Department of Medicine Centre Hospitalier de l'Université de " 'Montréal Montreal Québec Canada'}, { 'name': 'Department of Pediatrics CHU Sainte‐Justine Montreal Québec ' 'Canada'}], 'family': 'Bégin', 'given': 'Philippe', 'sequence': 'additional'}, { 'affiliation': [ {'name': 'Canadian Blood Services Ottawa Ontario Canada'}, { 'name': 'Department of Pathology and Molecular Medicine Kingston Health ' "Sciences Centre and Queen's University Kingston Ontario Canada"}, { 'name': 'Department of Laboratory Medicine and Molecular Diagnostics ' 'Sunnybrook Health Sciences Centre Toronto Ontario Canada'}, { 'name': 'Department of Laboratory Medicine and Pathobiology University of ' 'Toronto Toronto Ontario Canada'}], 'family': 'Callum', 'given': 'Jeannie', 'sequence': 'additional'}, { 'ORCID': 'http://orcid.org/0000-0003-0943-8853', 'affiliation': [ { 'name': 'Michael G. DeGroote Centre for Transfusion Research McMaster ' 'University Hamilton Ontario Canada'}, { 'name': 'Department of Medicine McMaster University Hamilton Ontario ' 'Canada'}], 'authenticated-orcid': False, 'family': 'Arnold', 'given': 'Donald M.', 'sequence': 'additional'}, { 'ORCID': 'http://orcid.org/0000-0003-3454-6266', 'affiliation': [ { 'name': 'Department of Health Research Methods, Evidence, and Impact ' 'McMaster University Hamilton Ontario Canada'}], 'authenticated-orcid': False, 'family': 'Xie', 'given': 'Feng', 'sequence': 'additional'}], 'container-title': 'Transfusion', 'container-title-short': 'Transfusion', 'content-domain': {'crossmark-restriction': True, 'domain': ['onlinelibrary.wiley.com']}, 'created': {'date-parts': [[2024, 3, 21]], 'date-time': '2024-03-21T12:44:38Z', 'timestamp': 1711025078000}, 'deposited': { 'date-parts': [[2024, 4, 9]], 'date-time': '2024-04-09T19:00:49Z', 'timestamp': 1712689249000}, 'funder': [ { 'DOI': '10.13039/501100000024', 'award': ['447352'], 'doi-asserted-by': 'publisher', 'name': 'Canadian Institutes of Health Research'}], 'indexed': {'date-parts': [[2024, 4, 10]], 'date-time': '2024-04-10T00:36:52Z', 'timestamp': 1712709412506}, 'is-referenced-by-count': 0, 'issue': '4', 'issued': {'date-parts': [[2024, 3, 21]]}, 'journal-issue': {'issue': '4', 'published-print': {'date-parts': [[2024, 4]]}}, 'language': 'en', 'license': [ { 'URL': 'http://creativecommons.org/licenses/by-nc-nd/4.0/', 'content-version': 'vor', 'delay-in-days': 0, 'start': { 'date-parts': [[2024, 3, 21]], 'date-time': '2024-03-21T00:00:00Z', 'timestamp': 1710979200000}}], 'link': [ { 'URL': 'https://onlinelibrary.wiley.com/doi/pdf/10.1111/trf.17777', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'member': '311', 'original-title': [], 'page': '606-614', 'prefix': '10.1111', 'published': {'date-parts': [[2024, 3, 21]]}, 'published-online': {'date-parts': [[2024, 3, 21]]}, 'published-print': {'date-parts': [[2024, 4]]}, 'publisher': 'Wiley', 'reference': [ {'DOI': '10.1056/NEJMoa2031893', 'doi-asserted-by': 'publisher', 'key': 'e_1_2_9_2_1'}, {'DOI': '10.1186/s13063-021-05235-3', 'doi-asserted-by': 'publisher', 'key': 'e_1_2_9_3_1'}, {'DOI': '10.1038/s41591-021-01488-2', 'doi-asserted-by': 'publisher', 'key': 'e_1_2_9_4_1'}, { 'DOI': '10.1016/S0140-6736(21)00897-7', 'doi-asserted-by': 'publisher', 'key': 'e_1_2_9_5_1'}, { 'DOI': '10.1001/jamainternmed.2021.6850', 'doi-asserted-by': 'publisher', 'key': 'e_1_2_9_6_1'}, {'DOI': '10.1186/s12879-021-06829-7', 'doi-asserted-by': 'publisher', 'key': 'e_1_2_9_7_1'}, {'DOI': '10.1001/jama.2021.18178', 'doi-asserted-by': 'publisher', 'key': 'e_1_2_9_8_1'}, { 'article-title': 'Consolidated health economic evaluation reporting standards 2022 ' '(CHEERS 2022) statement: updated reporting guidance for health economic ' 'evaluations', 'author': 'Don H', 'journal-title': 'BMJ', 'key': 'e_1_2_9_9_1', 'volume': '376', 'year': '2022'}, {'DOI': '10.1007/s11136-011-9903-x', 'doi-asserted-by': 'publisher', 'key': 'e_1_2_9_10_1'}, { 'DOI': '10.1097/MLR.0000000000000447', 'doi-asserted-by': 'publisher', 'key': 'e_1_2_9_11_1'}, { 'key': 'e_1_2_9_12_1', 'unstructured': 'Information CIfH.COVID‐19 hospitalization and emergency department ' 'statistics [product release].2022.'}, {'DOI': '10.1002/hec.635', 'doi-asserted-by': 'publisher', 'key': 'e_1_2_9_13_1'}, {'DOI': '10.1056/NEJMoa2103784', 'doi-asserted-by': 'publisher', 'key': 'e_1_2_9_14_1'}, { 'article-title': 'Convalescent plasma or hyperimmune immunoglobulin for people with ' 'COVID‐19: a living systematic review', 'author': 'Piechotta V', 'issue': '7', 'journal-title': 'Cochrane Database Syst Rev', 'key': 'e_1_2_9_15_1', 'volume': '7', 'year': '2020'}, {'DOI': '10.1056/NEJMoa2033700', 'doi-asserted-by': 'publisher', 'key': 'e_1_2_9_16_1'}, {'DOI': '10.1016/j.ijid.2021.06.034', 'doi-asserted-by': 'publisher', 'key': 'e_1_2_9_17_1'}, {'DOI': '10.1007/s11136-020-02688-y', 'doi-asserted-by': 'publisher', 'key': 'e_1_2_9_18_1'}, {'DOI': '10.1016/j.ijid.2022.07.063', 'doi-asserted-by': 'publisher', 'key': 'e_1_2_9_19_1'}, {'DOI': '10.1186/s12955-022-02033-6', 'doi-asserted-by': 'publisher', 'key': 'e_1_2_9_20_1'}, {'DOI': '10.1007/s10875-021-01193-2', 'doi-asserted-by': 'publisher', 'key': 'e_1_2_9_21_1'}, {'DOI': '10.1111/trf.16525', 'doi-asserted-by': 'publisher', 'key': 'e_1_2_9_22_1'}], 'reference-count': 21, 'references-count': 21, 'relation': {}, 'resource': {'primary': {'URL': 'https://onlinelibrary.wiley.com/doi/10.1111/trf.17777'}}, 'score': 1, 'short-title': [], 'source': 'Crossref', 'subject': ['Hematology', 'Immunology', 'Immunology and Allergy'], 'subtitle': [], 'title': 'Quality of life and <scp>cost‐effectiveness</scp> of convalescent plasma compared to standard ' 'care for hospitalized <scp>COVID</scp>‐19 patients in the <scp>CONCOR</scp>‐1 trial', 'type': 'journal-article', 'update-policy': 'http://dx.doi.org/10.1002/crossmark_policy', 'volume': '64'}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit